Please use this identifier to cite or link to this item:
https://hdl.handle.net/11147/5295
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fıratlıgil, Burcu | - |
dc.contributor.author | Biray Avcı, Çığır | - |
dc.contributor.author | Baran, Yusuf | - |
dc.date.accessioned | 2017-04-12T13:42:26Z | - |
dc.date.available | 2017-04-12T13:42:26Z | - |
dc.date.issued | 2013-04 | - |
dc.identifier.citation | Fıratlıgil, B., Biray Avcı, Ç., and Baran, Y. (2013). miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells. Journal of B.U.ON., 18(2), 437-441. | en_US |
dc.identifier.issn | 1107-0625 | - |
dc.identifier.uri | http://hdl.handle.net/11147/5295 | - |
dc.description.abstract | In this study we examined the expression levels of miR-17 which possesses oncogenic activities through downregulation of CDKN1A, p21 and E2F1 tumor suppressor genes, in imatinib sensitive and resistant chronic myeloid leukemia (CML) cells. On the other hand, we also determined the expression levels of miR-17 in response to tyrosine kinase inhibitors imatinib, nilotinib and dasatinib used for the treatment of CML. Methods: The expression profiles of miR-17 were analysed by Stem-Loop reverse transcription (RT) polymerase chain reaction (PCR). Results: The results revealed significant increase in the expression levels of miR-17 in imatinib sensitive and resistant cells compared to peripheral blood mononuclear cells (PBMCs). On the other hand, significant decrease was observed in miR-17 levels in response to imatinib, nilotinib and dasatinib. Conclusion: These results may imply that miR-17 can be used for diagnosis and treatment of CML. | en_US |
dc.description.sponsorship | Scientific and Technological Research Council of Turkey | en_US |
dc.language.iso | en | en_US |
dc.publisher | Zerbinis Medical Publications | en_US |
dc.relation.ispartof | Journal of B.U.ON. | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Chronic myeloid leukemia | en_US |
dc.subject | Dasatinib | en_US |
dc.subject | Drug resistance | en_US |
dc.subject | Imatinib | en_US |
dc.subject | MicroRNAs | en_US |
dc.subject | Nilotinib | en_US |
dc.title | miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells | en_US |
dc.type | Article | en_US |
dc.authorid | TR119193 | en_US |
dc.institutionauthor | Fıratlıgil, Burcu | - |
dc.institutionauthor | Baran, Yusuf | - |
dc.department | İzmir Institute of Technology. Molecular Biology and Genetics | en_US |
dc.identifier.volume | 18 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 437 | en_US |
dc.identifier.endpage | 441 | en_US |
dc.identifier.wos | WOS:000322750700020 | en_US |
dc.identifier.scopus | 2-s2.0-84879578050 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.pmid | 23818358 | en_US |
dc.identifier.scopusquality | N/A | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.openairetype | Article | - |
crisitem.author.dept | 04.03. Department of Molecular Biology and Genetics | - |
crisitem.author.dept | 04.03. Department of Molecular Biology and Genetics | - |
Appears in Collections: | Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
8
checked on Oct 4, 2024
WEB OF SCIENCETM
Citations
7
checked on Oct 5, 2024
Page view(s)
230
checked on Sep 30, 2024
Download(s)
86
checked on Sep 30, 2024
Google ScholarTM
Check
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.